# Filing Detail

Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-23-205011
Filing Date
2023-08-07
Accepted
2023-08-07 16:25:35
Documents
8

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | S-3 | d541146ds3.htm | S-3 | 456767
2 | EX-5.1 | d541146dex51.htm | EX-5.1 | 5548
3 | EX-23.1 | d541146dex231.htm | EX-23.1 | 1690
4 | EX-FILING FEES | d541146dexfilingfees.htm | EX-FILING FEES | 30137
5 | GRAPHIC | g541146g0806211048287.jpg | GRAPHIC | 2141
6 | GRAPHIC | g541146g13n03.jpg | GRAPHIC | 595199
7 | GRAPHIC | g541146g13n10.jpg | GRAPHIC | 680365
8 | GRAPHIC | g541146g45k65.jpg | GRAPHIC | 2936
| Complete submission text file | 0001193125-23-205011.txt |  | 2242641

Mailing Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453 6176515940
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-273769 | Film No.: 231147951
SIC: 2834 Pharmaceutical Preparations